Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome
Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome
复制标题
DOI：
10.1016/j.leukres.2010.06.029
复制
发表时间：
2011-03-01
影响因子：
2.7
通讯作者：
Papadaki, Helen A.
中科院分区：
文献类型：
--
作者：
Mavroudi, Irene;Pyrovolaki, Katerina;Papadaki, Helen A.
艾曲波帕是一种非肽基血小板生成素受体激动剂。我们评估了艾曲波帕对低风险骨髓增生异常综合征（MDS）患者巨核细胞生成的体外影响。与基线相比，0.1μg/mL浓度的艾曲波帕导致MDS患者和健康对照的巨核细胞集落数量显着增加。该剂量的艾曲波帕并未对患者CD34(+)细胞的增殖率或存活特征产生任何显着变化，这在临床上可能意味着对患者的结果产生不利影响。这些令人鼓舞的临床前数据支持了在临床中使用艾曲波帕来缓解低风险MDS患者血小板减少症的基本原理。 (C) 2010 Elsevier Ltd. 保留所有权利。
Eltrombopag is a nonpeptidyl thrombopoietin receptor agonist. We evaluated the ex vivo effect of eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndromes (MDSs). At a concentration of 0.1 mu g/mL, eltrombopag resulted in a significant increase in the number of megakaryocytic colonies in MDS patients and healthy controls compared to baseline. This dose of eltrombopag did not exert any significant change in the proliferation rate or the survival characteristics of patient CD34(+) cells that might clinically imply an unfavorable effect on patients' outcome. These encouraging preclinical data support the rationale of using eltrombopag in the clinic for alleviation of thrombocytopenia in lower risk MDS patients. (C) 2010 Elsevier Ltd. All rights reserved.